StockMirror — Stock Screener

AARTIPHARM Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Aarti Pharmalabs delivered strong Q2 FY27 results with revenue up 47% YoY to INR613 crores, EBITDA up 84% YoY to INR136 crores, and PAT of INR66 crores (2.75x YoY). EBITDA margin expanded to 22.2% from 17.7%. Growth was driven by CDMO (almost doubled QoQ), Xanthine volume and price gains, and API recovery. Management maintains 40-50% CDMO growth guidance and targets INR1,000 crores CDMO revenue in 2-3 years. Capacity expansions (Xanthine, Atali) are on track for full utilization by H2 FY27. Working capital increased due to higher sales and CDMO inventory build, but management considers it manageable. Overall, the call conveyed a positive outlook with confidence in achieving long-term growth targets.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management is pursuing revenue growth through CDMO expansion and capacity additions while also improving margins via favorable mix and pricing. They aim to balance both, with absolute gross margins increasing as more CDMO business is done.

About Aarti Pharmalabs Limited

Aarti Pharmalabs Limited (AARTIPHARM) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More